Explore the vast range of titles available.

Introduction Increasing access to multi‐month dispensing (MMD) of antiretroviral therapy (ART) supports treatment continuity and viral load suppression for people living with HIV (PLHIV) and reduces burden on health facilities. During the COVID‐19 response, PEPFAR worked with ministries of health to scale up MMD and expand eligibility to new groups of PLHIV, including children and pregnant/breastfeeding women. We analysed PEPFAR program data to understand the impact of the policy changes on actual practice. Methods We conducted a desk review in 21 PEPFAR‐supported countries to identify and collect official documentation released between March and June 2020 addressing changes to MMD guidance during the COVID‐19 response. MMD coverage, the proportion of all ART clients on MMD, was assessed in the calendar quarters preceding the COVID‐19 response (Q4 2019, October–December 2019; and Q1, January–March 2020) and the quarters following the start of the response (Q2 2020, April–June 2020; Q3 2020, July–September, 2020; Q4 2020, October–December 2020). We used the two‐proportion Z‐test to test for differences in MMD coverage pre‐COVID‐19 (Q4 2019) and during implementation of COVID‐19 policy adaptations (Q2 2020). Results and discussion As of June 2020, 16 of the 21 PEPFAR‐supported countries analysed adapted MMD policy or promoted intensified scale‐up of MMD in response to COVID‐19. MMD coverage for all clients on ART grew from 49% in Q4 2019 pre‐COVID‐19 to 72% in Q2 2020 during COVID‐19; among paediatric clients (< 15), MMD coverage increased from 27% to 51% in the same period. Adaptations to MMD policy were associated with a significantly accelerated growth in the proportion of clients on MMD (p < 0.001) for all populations, irrespective of age and dispensing interval. Conclusions Access to MMD markedly expanded during the COVID‐19 pandemic, supporting treatment continuity while mitigating exposure to COVID‐19 at health facilities. This model is beneficial in public health emergencies and during disruptions to the healthcare system. Outside emergency contexts, expanded MMD eligibility extends client‐centred care to previously excluded populations. The success in expanding MMD access during COVID‐19 should motivate countries to recommend broader MMD access as a new standard of care.

INTRODUCTION Distance to physicians may explain some of the disparities in Alzheimer's disease and related dementia (AD/ADRD) outcomes. METHODS We generated round trip distance between residences of decedents with AD/ADRD and the nearest neurologist and primary care physician in Washington State. RESULTS The overall mean distance to the nearest neurologist and primary care physician was 17 and 4 miles, respectively. Non‐Hispanic American Indian and/or Alaska Native and Hispanic decedents would have had to travel 1.12 and 1.07 times farther, respectively, to reach the nearest neurologist compared to non‐Hispanic White people. Decedents in micropolitan, small town, and rural areas would have had to travel 2.12 to 4.01 times farther to reach the nearest neurologist and 1.14 to 3.32 times farther to reach the nearest primary care physician than those in metropolitan areas. DISCUSSION These results underscore the critical need to identify strategies to improve access to specialists and primary care physicians to improve AD/ADRD outcomes. Highlights Distance to neurologists and primary care physicians among decedents with AD/ADRD American Indian and/or Alaska Native decedents lived further away from neurologists Hispanic decedents lived further away from neurologists Non‐metropolitan decedents lived further away from neurologists and primary care Decrease distance to physicians to improve dementia outcomes

Background and Aim Viral pneumonia is the most relevant clinical presentation of COVID‐19 which may lead to severe acute respiratory syndrome and even death. Eosinopenia was often noticed in patients with COVID‐19 pneumonia, but its role is poorly investigated. The aim of the present study was to investigate the characteristics and clinical outcomes of patients with COVID‐19 pneumonia and eosinopenia. Methods We revised the records of consecutive patients with COVID‐19 pneumonia admitted to our ER‐COVID‐19 area in order to compare clinical characteristics and outcomes of patients with and without eosinopenia. We considered the following clinical outcomes: 4‐weeks survival; need for intensive respiratory support; and hospital discharge. Results Out of first 107 consecutive patients with pneumonia and a positive COVID‐19 nasopharyngeal swab, 75 patients showed undetectable eosinophil count (absolute eosinopenia). At 4 weeks, 38 patients (38.4%) had required intensive respiratory treatment, 25 (23.4%) deceased and 42 (39.2%) were discharged. Compared with patients without absolute eosinopenia, patients with absolute eosinopenia showed higher need of intensive respiratory treatment (49.3% vs 13.3%, P < .001), higher mortality (30.6% vs 6.2%, P .006) and lower rate of hospital discharge (28% vs 65.6%, P < .001). Binary logistic regression analyses including neutrophil, lymphocyte, eosinophil, basophil and monocyte counts showed that absolute eosinopenia was an independent factor associated with 4‐weeks mortality, need for intensive respiratory support and hospital discharge. Conclusions Absolute eosinopenia is associated with clinical outcomes in patients with COVID‐19 pneumonia and might be used as a marker to discriminate patients with unfavourable prognosis.

Background Obesity is a risk factor associated with higher mortality at the acute phase of COVID‐19; however, its influence on post‐COVID symptoms is not known. Objective Our aim was to investigate if obesity is a risk factor for the presence of long‐term post‐COVID symptoms in hospitalised COVID‐19 survivors. Methods A multicentre case‐control study including patients hospitalised during the first wave of the pandemic was performed. Patients with obesity were recruited as cases. Two age‐ and sex‐matched patients without obesity per case were considered as controls. Clinical and hospitalisation data were collected from the hospital medical records. Patients were scheduled for a telephonic interview. A list of post‐COVID symptoms was systematically evaluated, but participants were free to report any symptom. Anxiety/depressive levels and sleep quality were evaluated with the hospital anxiety and depression scale (HADS) and Pittsburgh sleep quality index (PSQI), respectively. Results Overall, 88 patients with obesity and 176 without obesity were assessed 7.2 months after the hospital discharge. The most prevalent post‐COVID symptoms were fatigue and dyspnea. No significant difference in the prevalence of fatigue, dyspnea, anxiety, depression and limitations of daily living activities was observed between people with and without obesity. Obesity was independently associated with a greater number of post‐COVID symptoms (IRR 1.56, 95% CI 1.24‐1.95, P < .001) and poor sleep quality (OR 2.10, 95% CI 1.13‐3.83, P = .02). Conclusions This study found that obesity was associated with a greater number of long‐term post‐COVID symptoms and poor sleep quality in hospitalised COVID‐19 patients.

Lung cancer screening (LCS) reduces lung cancer-related mortality; however, uptake remains low compared with other cancer screening programmes. In this observational study, we report the impact of timed appointments and reminders on participation in our regional LCS programme.Initial uptake of timed appointments was 53.0% (n=17 274/32 593), higher than previously reported in the UK, while initial uptake of open invitations was 29.8% (n=10 246/34 371). Among initial non-responders, 17.5% (n=4263/24 400) completed triage following a reminder. The increased participation following reminders only partially offset the significant difference in initial uptake between the two appointment types.Timed appointments and reminders are strongly advocated to increase participation in national LCS programmes.

Infants form basic expectations about their physical and social environment, as indicated by their attention toward events that violate their expectations. Yet little is known about the neuronal processing of unexpected events in the infant brain. Here, we used rhythmic visual brain stimulation in 9-month-olds (N = 38) to elicit oscillations of the theta (4 Hz) and the alpha (6 Hz) rhythms while presenting events with unexpected or expected outcomes. We found that visually entrained theta oscillations sharply increased for unexpected outcomes, in contrast to expected outcomes, in the scalp-recorded electroencephalogram. Visually entrained alpha oscillations did not differ between conditions. The processing of unexpected events at the theta rhythm may reflect learning processes such as the refinement of infants’ basic representations. Visual brain-stimulation techniques provide new ways to investigate the functional relevance of neuronal oscillatory dynamics in early brain development.

INTRODUCTION Amyloid beta and tau pathology are the hallmarks of sporadic Alzheimer's disease (AD) and autosomal dominant AD (ADAD). However, Lewy body pathology (LBP) is found in ≈ 50% of AD and ADAD brains. METHODS Using an α‐synuclein seed amplification assay (SAA) in cerebrospinal fluid (CSF) from asymptomatic (n = 26) and symptomatic (n = 27) ADAD mutation carriers, including 12 with known neuropathology, we investigated the timing of occurrence and prevalence of SAA positive reactivity in ADAD in vivo. RESULTS No asymptomatic participant and only 11% (3/27) of the symptomatic patients tested SAA positive. Neuropathology revealed LBP in 10/12 cases, primarily affecting the amygdala or the olfactory areas. In the latter group, only the individual with diffuse LBP reaching the neocortex showed α‐synuclein seeding activity in CSF in vivo. DISCUSSION Results suggest that in ADAD LBP occurs later than AD pathology and often as amygdala‐ or olfactory‐predominant LBP, for which CSF α‐synuclein SAA has low sensitivity. Highlights Cerebrospinal fluid (CSF) real‐time quaking‐induced conversion (RT‐QuIC) detects misfolded α‐synuclein in ≈ 10% of symptomatic autosomal dominant Alzheimer's disease (ADAD) patients. CSF RT‐QuIC does not detect α‐synuclein seeding activity in asymptomatic mutation carriers. Lewy body pathology (LBP) in ADAD mainly occurs as olfactory only or amygdala‐predominant variants. LBP develops late in the disease course in ADAD. CSF α‐synuclein RT‐QuIC has low sensitivity for focal, low‐burden LBP.

Nucleophosmin 1 (NPM1) mutations occur in approximately one‐third cases of adult de novo acute myeloid leukemia (AML). Identification of NPM1 mutations is important for classification, risk stratification, tailored therapy, and monitoring minimal residual disease. Mutational analysis is widely used for detecting NPM1 mutations. Immunochemistry assessing abnormal cytoplasmic localization of NPM1 protein has been used as a surrogate marker for NPM1 mutations. We present a case of AML with mutated NPM1 that was missed by sequencing analysis but detected by immunohistochemistry. This case highlights the value of immunohistochemistry in identifying NPM1 mutations in a subset of AML cases.

INTRODUCTION Apolipoprotein E4 (APOE4) carriers’ tendency toward hypercholesterolemia may contribute to Alzheimer's disease (AD) risk through oxysterols, which traverse the blood‐brain barrier. METHODS Relationships between baseline plasma oxysterols, APOE status, serum lipids, and cognitive impairment risk were examined in 328 postmenopausal women from the Women's Health Initiative Memory Study. Women were followed for 25 years or until incident dementia or cognitive impairment. RESULTS Levels of 24(S)‐hydroxycholesterol (24‐OHC), 27‐hydroxycholesterol (27‐OHC), and 24‐OHC/27‐OHC ratio did not differ by APOE status (p’s > 0.05). Higher 24‐OHC and 27‐OHC were associated with higher total, low density lipoprotein (LDL), non‐high density lipoprotein (HDL), remnant, LDL/HDL, and total/HDL cholesterol and triglycerides (p’s < 0.05). Higher 24‐OHC/27‐OHC was associated with greater dementia risk (hazard ratio = 1.51, 95% confidence interval:1.02‐2.22), which interaction analyses revealed as significant for APOE3 and APOE4+, but not APOE2+ carriers. DISCUSSION Less favorable lipid profiles were associated with higher oxysterol levels. A higher ratio of 24‐OHC/27‐OHC may contribute to dementia risk in APOE3 and APOE4+ carriers.

IntroductionDespite the burgeoning literature on COVID-19, there has been little cross-national work on the correlates of mental health or its association with pandemic behaviours. We considered psychological distress, quarantine status, social distancing and self-medication in China and the UK.MethodsWe conducted online surveys in China (N=1135) and the UK (N=1293), beginning in March 2020. Participants indicated demographics, whether they were in quarantine, relationship status, social distancing, use of vitamins/traditional medicines and completed the K6 scale of psychological distress.Results19.1% of the respondents in China were at risk of severe mental illness (SMI: 95% CI 16.9% to 21.6%) and 16.6% (95% CI 14.6% to 18.8%) in the UK. Risk of SMI was among those in quarantine (OR 11.18 (95% CI 4.08 to 30.62); p=0.001) and in younger respondents (OR 2.61 (95% CI 1.01 to 6.79); p=0.048) although the latter effect was significant only in the UK. Risk of SMI was positively associated with self-medication (βs=0.17, p=0.001) and negatively with social distancing in China (country×SMI β=0.51, p=0.001), with further interactions for age and sex (social distancing), age, marital status and quarantine (self-medication).DiscussionAcross the countries, quarantine was associated with poorer mental health, while greater psychological distress was associated with greater self-medication rate. Future work should explore further cross-national variations in psychological health and behaviours during pandemics.